SquareMind Raises $18 Million for Skin Imaging Platform

SquareMind has raised $18 million in funding, including previously undisclosed pre-Series A financing, to enable high-quality, consistent skin exams and make them accessible at scale.

The latest financing round was led by Sonder Capital, a California-based venture fund co-founded by medical robotics pioneer and Intuitive Surgical founder Fred Moll, with participation by the Deeptech 2030 Fund, managed on behalf of the French government by a Bpifrance initiative, Adamed Technology, Calm/Storm Ventures, Teampact Ventures, and several prominent entrepreneurs.

The funding will help grow the company’s commercial, engineering, and customer support teams as it prepares to commercially launch the Swan robotic skin imaging platform in the United States and Europe, where demand for skin exams is high and rising.

Skin screening is the highest-volume procedure in dermatology. Demand continues to outpace capacity due to a rapidly aging population focused on skin care, with waitlists often stretching for months. Time constraints leave little room for thorough documentation, which is important for early detection as 80% of melanomas—a lethal skin cancer—are new lesions.

“We are excited to partner with Sonder Capital and all our investors as we ready ourselves to bring Swan to market and respond to the strong traction we are seeing from practices and hospitals,” SquareMind Co-Founder/CEO Ali Khachlouf said. “Dermatologists are operating under increasing pressure, facing strong cognitive load and fatigue. Our technology acts as their companion, helping to reduce this burden, optimize their time, and support comprehensive documentation so they can stay focused on patient care and clinical decision-making.”

Developed in collaboration with dermatologists, Swan is the world’s first robot to capture standardized, full-body dermoscopic skin imaging, acting as an augmented dermatoscope to view the entire skin surface at a level typically obtained when examining moles up close. Image acquisition is automated, completed in minutes, and seamlessly integrates into clinical workflows, according to the company.

Swan is paired with AI-based software supporting the review of skin imaging to help track new or changing moles over time, while physicians retain full clinical judgment.

“We fundamentally believe that advances in AI and medical robotics will reshape medical practice by automating routine procedures, optimizing clinical time, and expanding access to high-quality care,” Sonder Capital Managing Partner Kate Garrett stated. “SquareMind has developed a truly unique platform that has the potential to become the global standard of care in modern dermatology.”

In a private exam room, the patient stands before the Swan robot and is guided by visual and audio prompts while the robotic arm moves around them, capturing images of their skin. The session is short and contactless, ensuring a comfortable patient experience.

SquareMind is a Paris-based artificial intelligence and robotics company developing solutions for dermatology, with a mission to make high-quality skin exams more efficient and accessible. The company works closely with dermatologists to develop solutions that attempt to redefine the standard of care. Its flagship product, Swan, is U.S. Food and Drug Administration-listed and CE-marked, enabling commercial use in the United States and Europe.